Akeso Inc
HKEX:9926
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.8
77.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Akeso Inc
Akeso Inc
Operating Expenses
Akeso Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Akeso Inc
HKEX:9926
|
Operating Expenses
-¥2.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Operating Expenses
-¥23.5B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Operating Expenses
-¥7.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Operating Expenses
-¥3.1B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Operating Expenses
-¥4.9B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-30%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Operating Expenses
-¥649m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
Akeso Inc
Glance View
In the bustling landscape of biotechnology, Akeso Inc. emerges as a dynamic force addressing the dynamic and often daunting challenges of the medical world. Founded in 2012 and headquartered in China, this innovative company has made significant strides in the realm of biopharmaceuticals, particularly focusing on the research and development of novel therapies for oncology and immunology. Akeso Inc. differentiates itself through its comprehensive end-to-end approach, spanning discovery, clinical development, and commercialization. By leveraging its robust pipeline of therapeutic antibodies, the company constantly seeks to pioneer breakthroughs in cancer treatment and autoimmune disorders, thus driving its mission to enhance patient outcomes and address unmet medical needs. The economic engine of Akeso Inc. is driven by its ability to transform scientific research into viable therapeutic products. Revenue generation centers around the commercialization of their proprietary drugs, which often involves collaborations and strategic partnerships with major pharmaceutical players globally. These alliances not only expand the reach of Akeso's innovations but also provide essential capital and shared expertise that accelerate product advancement. The company's business model is further bolstered by licensing agreements and milestone payments, creating a steady stream of income as they navigate the rigorous pathways of drug approval and market entry. Through these ventures, Akeso Inc. not only secures its financial health but also continuously reinvests in its research endeavors, fueling a cycle of innovation that propels it forward in the competitive biotech arena.
See Also
What is Akeso Inc's Operating Expenses?
Operating Expenses
-2.3B
CNY
Based on the financial report for Dec 31, 2023, Akeso Inc's Operating Expenses amounts to -2.3B CNY.
What is Akeso Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-71%
Over the last year, the Operating Expenses growth was -11%. The average annual Operating Expenses growth rates for Akeso Inc have been -20% over the past three years , -71% over the past five years .
You don't have any saved screeners yet
